TQB2922 + TAS-102

TQB2922 + TAS-102 is a combination investigational therapy being studied primarily for advanced or metastatic colorectal cancer after failure of standard chemotherapy. - **TAS-102** (marketed as Lonsurf) is an oral combination of **trifluridine** (a nucleoside analogue that incorporates into DNA and disrupts DNA function, thus inhibiting tumor cell proliferation) and **tipiracil** (an inhibitor of thymidine phosphorylase, which prevents the degradation of trifluridine)[1][6]. - **TQB2922** is a novel agent; based on trial listings and sponsors, it is an investigational drug from Chia Tai Tianqing Pharmaceutical Group, though detailed mechanism information was not found in the provided results[3][4][5][8][10]. The combination is being studied in Phase Ib/II trials, with or without bevacizumab, for chemotherapy-failed, RAS/BRAF wild-type advanced colorectal cancer[3][4][5][8][10].

Brand names

Lonsurf

Other names

trifluridine + tipiracil + TQB2922